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Toward the end of December 2019, the COVID-19 out-
break resulted in massive fear worldwide. Although this 
outbreak initially occurred in Wuhan, a city in Hubei prov-
ince, China, it rapidly spread throughout the world. The 
World Health Organization (WHO) announced that the 
COVID-19 pandemic as a health emergency of public con-
cern on January 30, 2020.1 The pandemic has drastically 
impacted all industries and sectors worldwide, placing an 
immense burden on the health care system.2 COVID-19 has 
a wide array of clinical presentations ranging from non-
specific symptoms such as fever, fatigue, and diarrhea to 
severe respiratory and cardiovascular complications, 
including acute respiratory distress syndrome (ARDS) and 
multiple organ failure leading to mortality.3 As a result of 
the data gathered from numerous clinical trials conducted 
worldwide, there has been ongoing concern regarding the 
persistence of the SARS-CoV-2 virus in the post-acute 
period.4 Due to the limited understanding of the clinical 
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Abstract
Background: Current literature lacks characterization of the post-recovery sequelae among COVID-19 patients. This 
review characterizes the course of clinical, laboratory, radiological findings during the primary infection period, and the 
complications post-recovery. Primary care findings are presented for long-COVID care. Methods: Adhering to PRISMA 
guidelines, 4 databases were searched (PubMed, Embase, CINAHL Plus, Scopus) through December 5, 2020, using the 
keywords “COVID-19 and/or recovered and/or cardiovascular and/or long-term and/or sequelae and/or sub-acute and/or 
complication.” We included published peer-reviewed case reports, case series, and cross-sectional studies providing the 
clinical course of COVID-19 infection, and cardiopulmonary complications of patients who recovered from COVID-19, 
while making healthcare considerations for primary care workers. Results: We identified 29 studies across 9 countries 
including 37.9% Chinese and 24.1% U.S. studies, comprising 655 patients (Mean Age = 45) with various ethnical backgrounds 
including Asian and European. Based on the WHO COVID-19 severity classification scale, initial disease severity was mild 
for 377 patients and severe for 52 patients. Treatments during primary infection included corticosteroids, oxygen support, 
and antivirals. The mean value (in days) for complication onset after acute recovery was 28 days. Complete blood counts 
and RT-PCR tests were the most common laboratory results described. In 22 of the studies, patients showed signs of 
clinical improvement and were prescribed medications such as anticoagulants or corticosteroids. Conclusion: Post-
recovery infectious complications are common in long-COVID-19 patients ranging from mild infections to life-threatening 
conditions. International thoracic and cardiovascular societies need to develop guidelines for patients recovering from 
COVID-19 pneumonia, while focused patient care by the primary care physician is crucial to curb preventable adverse 
events. Recommendations for real-time and lab-quality diagnostic tests are warranted to establish point-of-care testing, 
detect early complications, and provide timely treatment.
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course of COVID-19, the possible long-term health impacts 
have not been elucidated. Our systematic review recognizes 
the sequelae of COVID-19 patients in the post-acute period 
to identify their persistent symptoms and clinical outcomes 
and to provide recommendations as the COVID-19 pan-
demic continues to spread.
Methods
For this systematic review, a literature search was per-
formed from December 1, 2019, through December 5, 
2020, to identify published articles that reported the out-
comes of COVID-19 patients after recovery. A systematic 
literature search was conducted on PubMed, Embase, 
CINAHL Plus, and Scopus to retrieve articles under the 
Preferred Reporting Items for Systematic Reviews 
(PRISMA) checklist criteria. The following search terms 
were used: “COVID-19 and/or recovered and/or cardiovas-
cular and/or long-term and/or sequelae and/or sub-acute 
and/or complication.” The search terms were kept broad to 
encompass all possibilities for applicable studies. There 
were no restrictions on the language of articles published.
Duplicates were removed using Endnote v9. After elimi-
nating duplicates, 3 investigators (AS, ZS, and MKC) inde-
pendently reviewed all titles and abstracts. The full texts of 
articles regarded as potentially eligible for consideration were 
extracted and screened for further analysis. Some records 
were also retrieved via cross-references from published papers 
(Umbrella review). Thereafter, eligible articles were selected 
for final analysis according to predefined inclusion and exclu-
sion criteria. Disagreements between the authors were 
resolved through consensus and active discussion.
Only human studies with clearly defined recovery, sur-
vival, other outcomes from acute COVID-19 were included. 
The patient population had mild, moderate, severe, or critical 
COVID-19 disease and a delineated of persistent symptoms 
and clinical outcomes in the post-acute period was essential 
for inclusion. The exclusion criteria consisted of review arti-
cles; animal studies; and the absence or unclear reporting of 
recovery status of COVID-19. As proposed by the National 
Institutes of Health, we employed a uniform severity classifi-
cation, ranging from mild, moderate, severe, and critical.5
1.  Mild Illness: Individuals who have any of the vari-
ous signs and symptoms of COVID-19 (eg, fever, 
cough, sore throat, malaise, headache, muscle pain, 
nausea, vomiting, diarrhea, loss of taste, and smell) 
but who do not have shortness of breath, dyspnea, or 
abnormal chest imaging.
2.  Moderate Illness: Individuals who show evidence 
of lower respiratory disease during clinical assess-
ment or imaging and who have an oxygen saturation 
(SpO2) ≥94% on room air at sea level.
3.  Severe Illness: Individuals who have SpO2 
<94% on room air at sea level, a ratio of arterial 
partial pressure of oxygen to fraction of inspired 
oxygen (PaO2/FiO2) <300 mm Hg, respiratory 
frequency >30 breaths/minutes, or lung infil-
trates >50%.
4.  Critical Illness: Individuals who have respiratory 
failure, septic shock, and/or multiple organ 
dysfunction.
The only exception to the severity scale employed is the 
paper by Wei6 which relied on the “Diagnosis and Treatment 
Protocol of Novel Coronavirus issued by the National 
Health Commission of the People’s Republic of China.” 
Data were tabulated into a shared spreadsheet customized 
for this review. All tables were optimized before commenc-
ing data entry using 6 sample articles included in the review 
to ensure optimal presentation of findings. Articles selected 
for the final analysis were independently graded by 2 
authors (AS and ZS) for quality using the Newcastle–
Ottawa Scale (NOS).
No funding was obtained for this study.
Results
The search yielded 1091 studies. After removing 431 dupli-
cates, 660 articles were reviewed for title and abstract. After 
the initial screening, only 167 articles met the inclusion cri-
teria and underwent full-text evaluation. Records that con-
sisted of commentaries, editorials, or reviews that did not 
meet our criteria were removed, generating a final list of 29 
articles (Figure 1).
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Figure 1. PRISMA flow diagram.
Characteristics of Included Studies
All studies included in this review were published through 
December 5, 2020. Twenty studies were case reports, 5 
were retrospective cohorts, 2 were prospective observa-
tional studies, 1 was a case-control, and 1 was a case series 
(Table 1). Nine countries were represented with the largest 
data derived from studies in China (37.9%) and the United 
States (24.1%). The total number of included participants 
was 655, with a mean age of 45, comprising of various eth-
nical backgrounds including Asian and European. A total of 
419 patients with mild symptoms and 59 patients with 
severe symptoms were included. Patient outcomes were 
notably well due to recovery from infection in 22 of the 
studies where they recovered or were prescribed medica-
tions for underlying thromboembolic conditions including 
anticoagulants.
Clinical Course and Pulmonary Complications of 
COVID-19 Recovered Patients
Table 2 summarizes the clinical course of SARS-CoV-2 
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a male predominance. About 12 studies reported complete 
clinical remission, 4 of them reported intensive care unit 
admission (ICU), 9 mentioned hospital admission, and an 
average of 34 days from the primary infection to the pres-
ence of complication was reported across 11 studies. The 
major complication during hospital stay was a respiratory 
failure even though it was only reported in only 2 studies. 
Treatment was provided in detail in 12 studies, encompass-
ing oxygen support, antivirals, antibiotics, corticosteroids, 
and anticoagulants. Most patients described shortness of 
breath, upper respiratory tract like symptoms, and dyspnea 
as main presenting features. RT-PCR tests and Computed 
Tomography (CT) Scans were the most commonly recom-
mended tests (Table 3).
Clinical Course and Complications of 
Cardiovascular COVID-19 Patients
Table 4 summarizes the clinical course and complications 
of cardiovascular COVID 19 patients. During our search, 
only 5 studies were classified in the cardiovascular section, 
with 1 study reported to have a severe COVID-19 popula-
tion. Chest pain, shortness of breath, and chest pain were 
noted, with patients in these groups aged 50 years or 
younger. Complete blood count (CBC) and inflammatory 
cardiac markers were recurrently elevated and 60% of the 
cases presented lesions visible through Cardiac Magnetic 
Resonance (CMR), diagnosed with myocarditis in 3 stud-
ies. An approximate period of a month was described from 
the period of primary infection to the onset of a complica-
tion. Treatments during hospital stay were not reported, 
except for Huang et al35 which reported antiviral, antibiotic, 
and oxygen support management during the hospital stay 
(not shown in the table).
Complications and Clinical Course of COVID-19 
Patients with Specific Characteristics
The complications and clinical course of all included 
COVID-19 patients with specific characteristics such as 
endocrine, hematological, ophthalmological, and neurolog-
ical details are described in Supplemental Table 1. Of all the 
aforementioned patients, 70% of them were hospitalized, 
and 30% of them were admitted to the intensive care unit 
(ICU). The patients were treated mainly with oxygen sup-
portive therapy, steroids, antibacterial, and antivirals. All 
patients were confirmed to have COVID-19 with a positive 
PCR test, initial complete blood work was followed, in 
addition to inflammatory markers and special panels 
according to each underlying comorbidity. Lung CT scans 
were followed in 60% of cases; 70% of the patients develop 
resolution of the acute clinical syndrome, even though a 
longer follow up study is suggested to observe the full reso-
lution of symptoms or complete basal return. In 4 (28.6%) 
of the pulmonary studies, pulmonary embolism (PE) was 
present. In 2 (14.3%) of studies, pneumothorax was noted, 
and recurrence of infection was observed in 5 (35.7%) of 
the studies. Of the cardiovascular studies, 4 (80%) required 
an additional test to detect abnormal functionality (Tables 3 
and 4). Relevant important points for primary care were 
extracted and described for cardiovascular and pulmonary 
cases (Tables 3 and 4). Despite the heterogeneity of the 
included articles, the need for guidelines, and the demand 
for follow up studies to describe duration or clinical course 
evolution is significant.
Discussion
This systematic review analyzes the cardio-pulmonary 
sequelae in recovered COVID-19 patients while making 
considerations for primary care. With the data gathered 
from numerous COVID-19 clinical studies conducted 
across the world, researchers have been able to demonstrate 
that despite apparent complete recovery from COVID-19, 
patients may suffer from post-recovery sequelae. However, 
there has been no consensus on the defining characteristics 
of post-acute COVID-19 syndrome. Commonly reported 
symptoms in the post-acute COVID-19 phase are fatigue, 
dyspnea, joint pain, and chest pain.36 Cardiopulmonary con-
sequences have been reported in the recovery phases, and 
have considerable implications for long-term health conse-
quences.29,37 A survey conducted by the Centers for Disease 
Control and Prevention (CDC) identified the contribution 
of 3 or more underlying medical conditions and age greater 
than 50 years as important predictors of not achieving base-
line health until 3 weeks after testing COVID-19 RT-PCR 
positive. Nevertheless, 20% of young individuals have not 
returned to baseline health after a median time of 16 days 
since testing positive for COVID-19.38 A critical discussion 
of post-acute COVID-19 syndrome is imperative as 
sequelae are observed among patients along the infection 
severity scale (ie, mild to critical).
Pulmonary
Wu et al39 report ARDS in 40% of patients infected with 
SARS-CoV-2 infection, with over 20% in the older age 
groups. Burnham et al40 find that persistent inflammation of 
alveolar epithelium and hypercytokinemia in SARS-CoV-2 
infection leads to fibroproliferative changes which include 
fibroblast accumulation and deposition of extracellular 
matrix collagen in the lung parenchyma. The resulting dis-
ruption of the balance between profibrotic and antifibrotic 
factors leads to pulmonary fibrosis which is observed in a 
subset of patients as protracted sequelae to ARDS.40 
Pulmonary fibrosis is characterized by the presence of an 
unusual interstitial pneumonia-like fibrotic abnormality on 
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linked to a more increased incidence of rapid progression of 
the disease.41-44
A prospective study was conducted by Liu et al including 
149 patients who were discharged from various hospitals in 
Wuhan, China following recovery from COVID-19 pneu-
monia. Patients were followed up during the first, second, 
and third-weeks post-discharge. The results showed that 
patients younger than 44 years had a significantly higher 
percentage of complete radiological resolution than patients 
who were older than 44 years. Out of the various lesions 
observed, the most predominant were ground-glass opacity 
in 83.9% of patients followed by a fibrous stripe in 54.4% 
and only 22.1% showed thickening of the adjacent pleura. 
The number of patients testing positive for each lesion 
decreased gradually over 3 weeks and the radiological reso-
lution was more evident in patients with ground-glass opac-
ity and fibrous stripe in the first and third weeks, respectively. 
Most residual lung abnormalities were absorbed throughout 
recovery, suggesting the importance of radiological assess-
ment 2 weeks post-discharge.30 The importance of determin-
ing the timing and standpoints of radiological resolution in 
COVID-19 patients can provide further insight into deciding 
which patient groups need long term monitoring.
Mo et al31 observed that COVID-19 survivors who had 
been discharged from the hospital demonstrated pulmonary 
function abnormalities, the most common among those 
being diffusion capacity impairment, followed by restric-
tive ventilatory defects. Zhao et al32 demonstrated both 
physiologic and radiographic abnormalities in a significant 
number of COVID-19 patients in discharged COVID 19 
patients after a 3-month follow-up period. In the INBUILD 
trial, Kolb and Vašáková45 note increased rates of forced 
vital capacity (FVC) decline and mortality over the 52 weeks 
in patients with usual interstitial pneumonia (UIP) like 
lesions when compared to those patients with other patterns 
of fibrosis. Several factors are involved in the extent to 
which pulmonary complications present in clinically recov-
ered patients; Salehi et al46 document the most significant 
being patients’ age, presence of comorbidities, and type of 
medications administered during COVID-19 management. 
Another point of contention is those patients with long-term 
sequelae who did not have either ARDS or PE during acute 
infection. While there is a paucity of pulmonary sequelae 
among patients who did not have either ARDS or PE during 
the acute infection, Han et al47 conducted a 6-month follow-
up of chest CT findings after severe COVID-19 pneumonia. 
Patients without ARDS were less likely to be associated 
with post-COVID radiological and functional changes.47 
There is a lack of detailed knowledge on the pathophysiol-
ogy of the disease, taking into consideration the available 
studies, following up on discharged COVID-19 patients, 
assessing them using radiological and pulmonary tests, and 
managing potential issues are all necessary precautionary 
measures.
Cardiovascular
Myocardial injury is defined by laboratory testing, namely 
by an increased troponin level, which has been documented 
as a severe COVID-19 sequela.48 A median of 71 days post 
COVID-19 diagnosis, cardiac involvement was reported 
by Puntmann et al29 in 78% patients, and 60% revealed 
myocardial inflammation on cardiac magnetic resonance 
imaging in a Germany study. Long et al49 reported common 
cardiovascular sequelae in COVID-19 as myocarditis, 
thromboembolic disease, and arrhythmias. The alterations 
in normal cardiovascular physiology, coagulation state, 
and basal metabolism observed, including those with 
RNA-sequencing analysis, reveal increased levels of 
angiotensin-converting enzyme-2 (ACE-2) in cardio-myo-
cytes thereby increasing the possibility of direct myocar-
dial tissue infection in high-risk patients.47,48 As per 
Siripanthong et al,50 the ACE-2 receptor on the myocar-
dium may be used by SARS-CoV-2 to gain entry into cells, 
triggering the release of massive amounts of pro-inflam-
matory cytokines, immune hyper-activation, and myocar-
dial tissue damage. Cardiac tropism, an impaired 
cardio-protective function of ACE2 downregulated by 
SARS-CoV-2, and elevated proinflammatory cytokine 
release are potential pathological mechanisms.51-53
Sardari et al13 write that myocarditis may occur due to 
the residual myocardial inflammation in COVID-19. 
Evidence of SARS-CoV-2 mRNA in the myocardium has 
been observed by Tavazzi et al54 and Wenzel et al55 on 
autopsy and endomyocardial biopsies, suggestive of myo-
carditis. Underlying cardiovascular disease (CVD) may 
predispose patients to SARS-CoV-2 myocarditis.55 Further, 
cardiovascular complications caused due to COVID-19 or 
prevalent before infection must be addressed. A meta-anal-
ysis finds that the pooled incidence of acute cardiovascular 
complications during the COVID-19 pandemic is 1.4%. 
However individuals with COVID-19 who presented with 
concomitant stroke were more likely to have pre-existing 
cardiovascular comorbidities not limited to arrhythmias, 
myocarditis, and thromboembolism, linked to severe 
COVID-19 infection. The patterns of large vessel occlu-
sions and multi-territory infracts suggests that thromboem-
bolism and/or cerebral thrombosis may potentially be 
causative pathways for COVID-19 disease.56 The mortality 
and morbidity due to cardiovascular complications in 
COVID-19 patients are higher when there is evidence of 
myocardial involvement, as implicated by Mitrani et al57 In 
the setting of myocarditis, myocyte lysis releases proteins 
with abnormal epitopes and with a similar structure to those 
present in the virus. Błyszczuk58 and Gangaplara et al59 
state that these can be recognized by major histocompatibil-
ity complex and seemingly add autoimmune components to 
cardiac injury. Chapman et al60 presume that these mecha-
nisms of tissue damage cause long-term complications in 
10 Journal of Primary Care & Community Health 
COVID-19 patients. Varga et al61 form an association 
between endothelitis and multi-organ failure with evidenc-
ing direct viral infection of the endothelium. Additionally, 
possible cytopathic effects and increased myocardial cell 
death after inducible SARS-CoV-2 on induced pluripotent 
stem cells (iPSC) have also been identified by Bose and 
McCarthy.62
Multiple studies have shown an increased rate of arrhyth-
mias in patients recovering from viral myocarditis. A study 
by Blagova et al63 revealed that among 19 cases of “idio-
pathic” arrhythmias, 78.9% were identified as immune-
mediated inflammatory after the endomyocardial biopsy 
was performed, finding cardiotropic viruses as etiologic 
agents. Since the beginning of the COVID-19 pandemic, 
thrombotic complications have been reported in critically ill 
patients. The term MicroCLOTS (microvascular COVID-
19 Lung Vessels Obstructive Thromboinflammatory syn-
drome) due to microvascular pulmonary thrombosis is 
currently being used in literature to describe manifestations 
of the disease. The high incidence of micro thrombosis in 
the lungs was noted in 80% autopsies of COVID-19 cases 
by Dolhnikoff et al64 Klok et al65 report the incidence of 
venous thromboembolism as 31%, leading to pulmonary 
embolism (80%) and arterial thrombosis (3.7%). Further 
studies are needed to specifically describe cardiovascular 
complications post COVID-19, especially screening for the 
incidence of heart failure. Close monitoring of patients is 
pertinent, even in cases with no signs of cardiovascular 
impairment.
Considerations for Primary Care
Although the impact of long-term COVID-19 sequelae is 
still unclear, a large number of patients will likely experi-
ence persistent symptoms, especially in those geographi-
cal regions where large outbreaks occurred. Various 
strategies are being evaluated not only to treat COVID-19 
patients but also to prevent as many detrimental compli-
cations as possible. Greenhalgh et al describe post-acute 
COVID-19 as “Long COVID,” which is a multisystem 
disease.66 Notably, cardio-pulmonary complications may 
occur after mild infections as well, requiring attention by 
primary care providers.66 For a general practitioner, it is 
essential to note improvements over 3 weeks and subse-
quent weeks/months. The symptoms may manifest in any 
bodily organ, however, the most common ones include 
cough (dry versus productive), fever, fatigue during long 
COVID. Uncommon symptomatology worth considering 
by the primary care practitioner includes mood swings, 
palpitations, anxiety, hypotension, and/or skin rashes 
(ie, maculopapular). The nonspecific (ie, lung burn, 
brain fog) versus the specific complications (ie, stroke, 
pulmonary embolism, myocarditis, heart failure) must 
be distinguished clinically upon a visit to a primary care 
practitioner and specific presentations recommended to 
specialist centers. A clinical insight for long COVID is the 
fact that the presentation during acute COVID does not 
directly relate to the severity of findings 6 months later 
(ie, if a patient had severe pneumonia on the acute onset, 
the sequelae may be less severe as compared to those who 
had less severe acute complications). Based on the lim-
ited evidence in published literature so far, patients with 
long COVID may have no access to specialist care. To 
improve patient outcomes, it is essential to adopt a com-
munity-based, interprofessional rehabilitation pattern of 
care by promoting remote technologies, telehealth 
appointments with a primary care physician, and adopting 
otherwise locally relevant solutions.
Recommendations
The implementation of a multi-disciplinary approach to 
identify, and prevent the impact of long-term health out-
comes of COVID-19 across different organs, including car-
diopulmonary, as well as the well-being of recovered patient 
groups is necessary to elucidate the potential classification 
of complications in post-acute COVID-19.67 An example of 
how rehabilitation can successfully be applied to post-
COVID-19 patient management is offered by Shan et al,68 
who describes the case of a woman at about 80 years of age 
gradually returning to her premorbid independent condition 
after severe COVID-19 complicated by acute respiratory 
distress syndrome (ARDS) following 10 days of post-acute 
inpatient pulmonary rehabilitation. Interestingly, current 
knowledge on the long-term impact of the SARS-CoV-2 
infection to an important degree comes from previous epi-
demics, caused by severe acute respiratory syndrome 
(SARS) and the Middle East respiratory syndrome (MERS). 
However, deficits associated with the current pandemic are 
expected to be more critical, given the magnitude of the 
pandemic.
A practical approach is to follow up on all hospitalized 
patients with chest radiography and oxygen saturation mea-
surements, as recommended by the British Thoracic 
Society.69 However, the American Thoracic Society/
European Respiratory Society does not make any sugges-
tion in favor of or against routine pulmonary function tests 
(PFTs), chest CT scans, transthoracic echocardiography 
(TTE), and cardiopulmonary exercise testing (CPET) 
within 30 to 60 days.70 Preliminary evidence suggests the 
development of respiratory sequelae as early as 2 weeks 
after discharge, especially among patients with elevated 
inflammatory markers and D-dimer levels.31,32 Data sug-
gests the frequent occurrence of pulmonary fibrosis, 
arrhythmias, and cardiomyopathies among survivors over 
2 months after recovery.29 All patients requiring further 
investigation may be referred to as pulmonologists and car-
diologists for further evaluation of pulmonary (PFTs and 
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chest CT scans) and cardiac (TTE and CPET) assessment 
within 2 to 3 months of recovery. It is also necessary to 
establish a baseline time to follow recovery. Admittedly, 
resource-limited settings may not be able to conduct such 
tests. Consequently, evidence suggests routine testing of 
pulmonary and cardiac sequelae in COVID-19 is beneficial 
within 30 to 90 days of discharge in all previously hospital-
ized patients.
Limitations
In the United States, 3 different phases of the pandemic 
have been documented. At the onset, in April, 2020 there 
was limited testing. During the second phase in July, 2020, 
social distancing among other factors contributed to infec-
tivity. However, testing was widely available to most of 
the public. The third phase at the onset of 2021 was poten-
tially connected with seasonal respiratory viruses. These 
are uncontrollable limitations in post-infection pulmo-
nary-cardiovascular tests that are presented with external 
factors contributing to varied test outcomes. The other 
limitation of our study relates to its retrospective nature. 
Many of the included studies were case reports and, there-
fore, findings may not be generalizable and the causality 
within those may not be fully proven. As the majority of 
the studies were from China, some of the presentations 
could be influenced by the ethnicity-related characteristics 
of the region.
Conclusion
With limited insight on the sequelae of COVID-19 infec-
tion, a holistic approach is required that incorporates pri-
mary care. Complications are frequently observed in 
patients recovering from COVID-19, ranging from mild to 
life-threatening conditions. Patients who presented with 
ARDS, PE, arrhythmia, myocarditis, or other cardiopul-
monary complications during the acute phase necessitate 
multi-speciality care and follow-up for long-COVID. It is 
currently unclear whether ARDS or other complications 
due to COVID-19 or other causative factors will have dif-
ferent long-term outcomes. Follow-up of clinically recov-
ered patients with cardiopulmonary imaging studies could 
be crucial for the evaluation of adverse events caused by 
SARS-CoV-2 infection. Primary health care forms a criti-
cal foundation for gatekeeping timely and effective sup-
port during the COVID-19 pandemic. Through primary 
care services, it is possible to provide rehabilitation and 
support to recovering patients in light of a greater volume 
of patients requiring rehabilitation in the post-acute 
COVID-19 infectious phase. Physicians across all health-
care levels should be alert on and monitor patients for pos-
sible adverse events after recovery from SARS-CoV-2 
infection. International societies ought to develop 
guidelines for patients recovering from COVID-19 and 
recommend the routine monitoring of these patients to 
establish cardiopulmonary testing, detect early complica-
tions, and provide timely treatment. Importantly, observa-
tional studies and clinical trials reporting data on acute 
and post-acute infectious phases will help elucidate the 
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OCT optical coherence tomography
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PE pulmonary embolism
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PO2 partial pressure oxygen (Po2)
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